Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech has jettisoned the molecule and shifted its focus to a preclinical ...

New York, New York-- (Newsfile Corp. - February 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

The European Medicines Agency’s positive opinion for ivermectin-albendazole for treating soil-transmitted helminth infections ...

It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after ...

The study links exertional heat stroke to chronic disorders, revealing impacts on body mass regulation and heart health, ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

If you have obesity, losing even a little weight helps not only improve your overall health, but also prevent liver issues such as MASH.